Transcript Document

Supersensitive magnetocardiographic system
for early recognition, precise diagnostics and
monitoring of heart diseases
12.10.2006
Kiev
Dr.Volodymyr Sosnytskyy
+38(044)5013072
[email protected]
Kiev Medical Group, Ltd.
Kiev
1
Proprietary information statement
• The technology material presented in this talk is
available for licensing or joint product development.
• None of the slides contain any confidential or
proprietary information which would prevent patenting
the technology.
2
Problem Description & Market Need
- Ischemic heart disease is the leading cause of death in Western countries.
-
The early noninvasive diagnosis of ischemia is one of the major clinical
problems that could benefit from the additional information provided by MCG.
-
MCG can identify propensity to ventricular arrhythmias, in heart diseases ,
independently of other clinical variables.
-
Contactless MCG can be ideal for research and development of new drugs
and for experimental evaluation of gene therapy.
-
The vicious circle: lack of clinical equipment -> clinician skepticism ( lack of
experience) -> lack of evidence-based clinical benefit -> no real market -> lack
of investment -> lack of development of clinical equipment.
3
Brief technology description
• MCG is the measurement of
magnetic fields emitted by the
human heart from small currents
by electrically active cells of the
heart muscle.
• MCG is a completely noninvasive
method that permits the
registration of cardiac electrical
activity at multiple site in a plane
above the chest cage without the
need for electrodes.
• MCG is both a method to record
cardiac signals and to provide 3D
functional imaging of cardiac
electrophysiology.
4
Averaged MCG
36-channels
Normal MCG
Map of magnetic field
distribution on Tapex
Map of current density
distribution on Tapex
5
Advantages
• MCG is modern imaging and quantitative analysis technique for
detection abnormal difference in electrophysiological cardiac
phenomena
• Magnetocardiography (MCG) is a noninvasive and risk-free
technique for contactless surface mapping of the magnetic fields
generated by the electrical activity of the heart.
• This SQUID-based MCG system has a high potential for health care,
especially because it could be used in hospital environments without
expensive and inflexible magnetic shielded rooms.
• Recent availability of budget-price multichannel minisystems for
unshielded MCG.
• MCG has been accepted as a clinical tool.
6
Experimental results
MCG – Animal Studies
PHANTOM AND SOURCE
MODELING
7
Clinical Trials (CAD with normal ECG vs. Controls)
Sensitivity & Specificity of MCG in CAD with normal ECG
PET
- 90 -
Stress-EchoCG
Stress Scintigraphy
- 80 -
MCG 90.5 %
- 70 -
PET
MCG 84.6 %
Stress Scintigraphy
Stress-EchoCG
Exercise-ECG
- 60 - 50 -
Sensitivity
Specificity
- 40 Exercise-ECG
Holter monitoring
ECG at rest
- 30 Holter monitoring
- 20 - 10 -
ECG at rest
8
Stage of development
• System is ready for application
• Clinical Trials: detection of myocardial ischemia
and arrhythmogenic risk assessment
9
Targeted Market Segment
• MCG can be used for noninvasive diagnosis of cardiac events related to :
- coronary artery disease (CAD),
- safety of all medical drugs with respect to the drugs potential to cause
heart arrhythmia,
- early detection of graft rejection after cardiac transplantation,
- pathophysiological role and therapeutic potential of stem cells .
Introduction of MCG diagnostics into routine clinical practice can
improve patient outcomes, decrease mortality and risks, increase comfort
and significantly reduce cost of health care.
The cost of commercially available few-channel systems for unshielded
MCG range between 200,000 and 500,000 US$
10
Competition
•
More expensive or invasive methods:
- Stress-echocardiography,
- Single photon emission computed tomography
(SPECT)
- Coronary angiography
The cost of the equipment for MCG differs widely as
function of approach prefered.
Small unshielded systems can now be operated by
nurses or research technicians
11
Competitive Matrix
Important product
or technology
characteristics
Cost-effectiveness
------------------------automated
The evaporation
rate
L/day
Solution of the
Inverse problem
(Software)
Costs
( X 1000 )
Kiev Medical
Group, Ltd.
high
complitely
1,7
modern
200-300
Cardio Mag
Imaging Inc.
Cryoton Co.Ltd
low
middle
semi
semi
2,5
2-3
old
modern
> 300-500
> 300
12
Opportunities
We look forward on international
collaboration for :
• clinical trials
• joint product development
13
Contact information
Dr.Volodymyr Sosnytskyy
+38(044)5013072
[email protected]
Kiev Medical Group, Ltd.
Kiev
14